Comparative Pharmacology
Head-to-head clinical analysis: DIAMOX versus DORZOLAMIDE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAMOX versus DORZOLAMIDE HYDROCHLORIDE.
DIAMOX vs DORZOLAMIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
One drop of 2% solution in the affected eye(s) three times daily.
None Documented
None Documented
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; pH-dependent; alkaline urine increases elimination.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor